Next Article in Journal
Management of Arthralgias Associated with Aromatase Inhibitor Therapy
Previous Article in Journal
Minds That Matter: 2007 Gairdner International Awards Lectures
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 14
Issue s1
10.3747/co.2007.153
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Cancer Therapy Disparity: Unequal Access to Breast Cancer Therapeutics and Drug Funding in Canada

by
S. Verma
1,*,
S. Sehdev
2 and
A. A. Joy
3
1
Division of Medical Oncology, Toronto–Sunnybrook Regional Cancer Centre, Sunnybrook and Women’s College Health Sciences Centre, Toronto, ON, Canada
2
The Oncology Group, William Osler Health Centre, Brampton, ON, Canada
3
Cross Cancer Institute, Edmonton, AB, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2007, 14(s1), 3-10; https://doi.org/10.3747/co.2007.153
Submission received: 5 September 2007 / Revised: 4 October 2007 / Accepted: 9 November 2007 / Published: 1 December 2007

Abstract

Adjuvant therapy has made a significant contribution in reducing breast cancer–specific mortality. Standard chemotherapeutics and tamoxifen have been the mainstay treatment for years, but recent clinical evidence supports the use of novel small-molecule therapy and aromatase inhibitor therapy in selected settings, challenging not only the traditional paradigm of breast cancer treatment, but also provincial funding of oncologic care across Canada. The disparity in access to aromatase inhibitor therapy for postmenopausal women with early-stage hormone-sensitive breast cancer across Canada is highlighted as an example.
Keywords: aromatase inhibitors; breast cancer; endocrine therapy aromatase inhibitors; breast cancer; endocrine therapy

Share and Cite

MDPI and ACS Style

Verma, S.; Sehdev, S.; Joy, A.A. Cancer Therapy Disparity: Unequal Access to Breast Cancer Therapeutics and Drug Funding in Canada. Curr. Oncol. 2007, 14, 3-10. https://doi.org/10.3747/co.2007.153

AMA Style

Verma S, Sehdev S, Joy AA. Cancer Therapy Disparity: Unequal Access to Breast Cancer Therapeutics and Drug Funding in Canada. Current Oncology. 2007; 14(s1):3-10. https://doi.org/10.3747/co.2007.153

Chicago/Turabian Style

Verma, S., S. Sehdev, and A. A. Joy. 2007. "Cancer Therapy Disparity: Unequal Access to Breast Cancer Therapeutics and Drug Funding in Canada" Current Oncology 14, no. s1: 3-10. https://doi.org/10.3747/co.2007.153

APA Style

Verma, S., Sehdev, S., & Joy, A. A. (2007). Cancer Therapy Disparity: Unequal Access to Breast Cancer Therapeutics and Drug Funding in Canada. Current Oncology, 14(s1), 3-10. https://doi.org/10.3747/co.2007.153

Article Metrics

Back to TopTop